2025-04-08 17:45:01
Latest Post
Godrej Properties delivers its highest ever quarterly and full year bookings
Poonawalla Fincorp Launches Shopkeeper Loan Business
Revolt Motors Expands to 200 Dealerships, Targets 400 by FY26
Sobha Ltd - Real Estate Operational Update - Q4 FY 2024-25
Lemon Tree Hotels signs a new property in DarjeelingStock Report
Gland Pharma Ltd Q1FY22 consolidated PAT rises to Rs. 350.65 crores
Posted On : 2021-07-21 16:28:19( TIMEZONE : IST )
Gland Pharma Ltd has reported financial results for the period ended June 30, 2021.
Financial Results (Q1 FY2021-22) - QoQ Comparison
The company has reported total income of Rs.1215.73 crores during the period ended June 30, 2021 as compared to Rs.934.96 crores during the period ended March 31, 2021.
The company has posted net profit / (loss) of Rs.350.65 crores for the period ended June 30, 2021 as against net profit / (loss) of Rs.260.40 crores for the period ended March 31, 2021.
The company has reported EPS of Rs.21.37 for the period ended June 30, 2021 as compared to Rs.15.88 for the period ended March 31, 2021.
| Financials | Q1 FY2021-22 | Q4 FY2020-21 | % Change |
| Total Income | ₹ 1215.73 crs | ₹ 934.96 crs |  30.03% |
| Net Profit | ₹ 350.65 crs | ₹ 260.40 crs | 34.66% |
| EPS | ₹ 21.37 | ₹ 15.88 | 34.57% |
Financial Results (Q1 FY2021-22) - YoY Comparison
The company has reported total income of Rs.1215.73 crores during the period ended June 30, 2021 as compared to Rs.916.28 crores during the period ended June 30, 2020.
The company has posted net profit / (loss) of Rs.350.65 crores for the period ended June 30, 2021 as against net profit / (loss) of Rs.313.59 crores for the period ended June 30, 2020.
The company has reported EPS of Rs.21.37 for the period ended June 30, 2021 as compared to Rs.20.24 for the period ended June 30, 2020.
| Financials | Q1 FY2021-22 | Q1 FY2020-21 | % Change |
| Total Income | ₹ 1215.73 crs | ₹ 916.28 crs | 32.68% |
| Net Profit | ₹ 350.65 crs | ₹ 313.59 crs | 11.82% |
| EPS | ₹ 21.37 | ₹ 20.24 | 5.58% |
Commenting on the results, Mr. Srinivas Sadu, MD & CEO of Gland Pharma said "In spite of the challenges from the second wave of COVID in the country, in terms of manpower availability and supply chain bottlenecks, Gland Pharma has managed to deliver strong quarterly results. The revenue for the quarter stood at ₹11,539 Mn, which is a Y-o-Y revenue growth of 31%, with a PAT margin of 29%, which is ₹3,507 Mn. Our execution capabilities, be it uninterrupted commercial supplies, project commissioning or new product launches, is what underpins our strong performance in this quarter. It was an important milestone for the company to launch our first set of Penem products for the US market during the quarter. The dedicated suite for vaccine drug product fill finish is now ready for vaccine commercial production, while the tech transfer for the drug substance manufacturing is ongoing. We continue to support the nation by ramping up production of essential COVID drugs."
